Related Experiment Video
Updated: Jun 6, 2026
04:22
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
Published on: March 30, 2017
Pulmonary formulations: what remains to be done?
Jeffry G Weers1, John Bell, Hak-Kim Chan
1Novartis Pharmaceutical Corp., San Carlos, California 94070, USA. jeff.weers@novartis.com
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|December 8, 2010
Summary
Future pulmonary drug delivery innovations require integrating biology and particle engineering for targeted delivery. Advances in controlled release, cellular targeting, and bioavailability are crucial for effective aerosol formulations.
Area of Science:
- Pharmaceutical Sciences
- Biotechnology
- Materials Science
Background:
- Pulmonary drug delivery has seen significant advances over 50 years.
- Innovation is increasingly driven by the intersection of biology and particle engineering.
Purpose of the Study:
- To outline key areas for future innovation in aerosol formulations for pulmonary delivery.
- To emphasize the need for improved understanding of biological processes for formulation design.
Main Methods:
- Discusses the need for improved understanding of particle clearance, cellular targeting, and drug absorption.
- Highlights the necessity for advancements in controlled release, regional lung targeting, and active targeting moieties.
- Addresses formulation strategies for systemic bioavailability of macromolecules and intracellular delivery of nucleic acids like siRNA and DNA.
Main Results:
- Identifies critical areas for formulation development: controlled release, regional targeting, active targeting, systemic bioavailability, intracellular delivery, and dose consistency.
- Suggests novel excipients and particle engineering strategies are essential for future progress.
- Underscores the importance of considering pharmacoeconomics and diverse market stakeholders.
Conclusions:
- Future pulmonary delivery innovation hinges on a multidisciplinary approach combining biological insights with advanced particle engineering.
- Addressing formulation challenges in controlled release, targeting, and bioavailability is key to developing next-generation inhaled therapeutics.
- Balancing technological advancement with economic viability and market needs is imperative for successful translation.
Related Concept Videos
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:25Pulmonary Function Tests
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...